Retatrutide

Retatrutide occupies a genuinely novel position in metabolic pharmacology: it is a single molecule engineered to agonise three receptors at once, GIP, GLP-1, and glucagon. That third target sets it apart from semaglutide, a GLP-1-only agonist, and from tirzepatide, which engages GIP and GLP-1 alone. The added glucagon receptor activity is thought to recruit hepatic and thermogenic pathways that lift energy expenditure, giving researchers a tool with a signalling breadth no earlier incretin compound could offer. Phase 2 findings published in the New England Journal of Medicine recorded pronounced reductions in body weight across dosing cohorts over a 48-week window, and the molecule is currently in Phase 3 investigation under Eli Lilly. For laboratories working on incretin biology and multi-receptor agonism, Retatrutide is a reference compound for probing how simultaneous activation of three metabolic receptors reshapes glucose handling, lipid turnover, appetite signalling, and whole-body energy balance. Its triple-agonist design also opens a window onto receptor crosstalk and the combined output of incretin and glucagon signalling in metabolic disease models.